| 1.33 0.02 (1.53%) | 09-11 12:09 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.76 | 1-year : | 1.92 |
| Resists | First : | 1.51 | Second : | 1.64 |
| Pivot price | 1.37  |
|||
| Supports | First : | 1.28 | Second : | 1.07 |
| MAs | MA(5) : | 1.32 |
MA(20) : | 1.4 |
| MA(100) : | 1.36  |
MA(250) : | 1.34 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 3.9 |
D(3) : | 7 |
| RSI | RSI(14): 38 |
|||
| 52-week | High : | 2.5 | Low : | 0.57 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ INM ] has closed above bottom band by 17.5%. Bollinger Bands are 50.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.34 - 1.35 | 1.35 - 1.36 |
| Low: | 1.27 - 1.28 | 1.28 - 1.29 |
| Close: | 1.3 - 1.31 | 1.31 - 1.32 |
InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.
Wed, 09 Sep 2026
[S-4/A] InMed Pharmaceuticals Inc. Amended Business Combination Registration | INM SEC Filing - Form S-4/A - Stock Titan
Wed, 09 Sep 2026
$490M backs proposed migraine merger at InMed Pharmaceuticals (INM)—what legacy holders keep - Stock Titan
Wed, 09 Sep 2026
InMed Pharmaceuticals Inc. FY 2026: Revenue $3.18M, EPS ($3.12) — 10-K Summary - TradingView
Wed, 09 Sep 2026
About $490 million in financing is expected before a proposed merger. InMed still needs shareholder approval. - Stock Titan
Wed, 09 Sep 2026
InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update - newsfilecorp.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 5 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 84.6 (%) |
| Shares Short | 72 (K) |
| Shares Short P.Month | 119 (K) |
| EPS | -1.48 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.07 |
| Profit Margin | -172.2 % |
| Operating Margin | -162.8 % |
| Return on Assets (ttm) | -54.7 % |
| Return on Equity (ttm) | -112.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.32 |
| Sales Per Share | 0.92 |
| EBITDA (p.s.) | -1.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.89 |
| PEG Ratio | 0 |
| Price to Book value | 0.62 |
| Price to Sales | 1.4 |
| Price to Cash Flow | -0.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|